DK2275086T3 - Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf - Google Patents

Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf

Info

Publication number
DK2275086T3
DK2275086T3 DK10160099.7T DK10160099T DK2275086T3 DK 2275086 T3 DK2275086 T3 DK 2275086T3 DK 10160099 T DK10160099 T DK 10160099T DK 2275086 T3 DK2275086 T3 DK 2275086T3
Authority
DK
Denmark
Prior art keywords
administration
methods
reduced volume
glatiramer acetate
volume formulation
Prior art date
Application number
DK10160099.7T
Other languages
Danish (da)
English (en)
Inventor
Ayelet Altman
Doris Saltkill
Dalton L Tomlinson
Tomer El-Gad
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2275086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK2275086T3 publication Critical patent/DK2275086T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK10160099.7T 2009-07-15 2010-04-15 Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf DK2275086T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29

Publications (1)

Publication Number Publication Date
DK2275086T3 true DK2275086T3 (da) 2012-07-09

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10160099.7T DK2275086T3 (da) 2009-07-15 2010-04-15 Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf

Country Status (19)

Country Link
US (3) US20110060279A1 (enExample)
EP (2) EP2275086B1 (enExample)
JP (1) JP2012533540A (enExample)
AR (1) AR077484A1 (enExample)
AT (1) ATE549013T1 (enExample)
AU (1) AU2010273234A1 (enExample)
BR (1) BR112012000878A2 (enExample)
CA (1) CA2697570C (enExample)
DK (1) DK2275086T3 (enExample)
EA (1) EA201270167A1 (enExample)
ES (1) ES2383347T3 (enExample)
HR (1) HRP20120349T1 (enExample)
IL (1) IL217240A0 (enExample)
MX (1) MX2012000687A (enExample)
PL (1) PL2275086T3 (enExample)
PT (1) PT2275086E (enExample)
RS (1) RS52367B (enExample)
WO (1) WO2011008274A2 (enExample)
ZA (1) ZA201200586B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
ES2383347T3 (es) * 2009-07-15 2012-06-20 Teva Pharmaceutical Industries, Ltd. Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP2013541010A (ja) 2010-10-11 2013-11-07 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
AU2012323345A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2014029621A1 (en) * 2012-08-20 2014-02-27 Carebay Europe Ltd Automatic injection device
NZ630421A (en) 2012-10-10 2018-07-27 Teva Pharma Biomarkers predictive for clinical response for glatiramer acetate
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
KR101738889B1 (ko) * 2013-03-08 2017-05-23 테바 파마슈티컬 인더스트리즈 리미티드 주사기용 재사용 가능한 주입기 장치
AU2014229581B2 (en) * 2013-03-08 2016-12-22 Teva Pharmaceutical Industries Limited Re-useable injector device for syringe
US8591463B1 (en) * 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
RU2728195C2 (ru) 2014-02-26 2020-07-28 Аллерган, Инк. Устройство доставки внутриглазного имплантата и способы его использования
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7193448B2 (ja) 2016-08-31 2022-12-20 マピ ファーマ リミテッド 酢酸グラチラマーを含むデポシステム
WO2018083697A1 (en) * 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
WO2019036363A1 (en) 2017-08-14 2019-02-21 Progenity Inc. TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE55260T1 (de) * 1985-10-11 1990-08-15 Duphar Int Res Automatische spritze.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) * 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
EP1572271A1 (de) * 2002-11-25 2005-09-14 Tecpharma Licensing AG Autoinjektor mit rückstellbarer auslösesicherung
JP2007507541A (ja) * 2003-10-03 2007-03-29 ベイヒル セラピューティクス インコーポレーティッド 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
EP1796710A4 (en) * 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
US7560100B2 (en) * 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
ES2331015T3 (es) * 2004-10-29 2009-12-18 Sandoz Ag Proceso para la preparacion de un glatiramero.
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
TWI527603B (zh) * 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
CA2702437C (en) 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
ES2383347T3 (es) 2009-07-15 2012-06-20 Teva Pharmaceutical Industries, Ltd. Formulación de volumen reducido de acetato de glatirámero y procedimientos de administración

Also Published As

Publication number Publication date
AU2010273234A1 (en) 2012-02-23
AR077484A1 (es) 2011-08-31
WO2011008274A3 (en) 2011-09-22
ES2383347T3 (es) 2012-06-20
JP2012533540A (ja) 2012-12-27
EP2275086B1 (en) 2012-03-14
EP2275086A1 (en) 2011-01-19
US20110066112A1 (en) 2011-03-17
MX2012000687A (es) 2012-09-07
CA2697570A1 (en) 2010-06-22
ATE549013T1 (de) 2012-03-15
ZA201200586B (en) 2013-10-30
EA201270167A1 (ru) 2012-08-30
WO2011008274A2 (en) 2011-01-20
HK1152249A1 (en) 2012-02-24
HRP20120349T1 (hr) 2012-07-31
US9018170B2 (en) 2015-04-28
BR112012000878A2 (pt) 2019-09-24
PT2275086E (pt) 2012-05-18
CA2697570C (en) 2011-11-01
WO2011008274A4 (en) 2011-11-10
IL217240A0 (en) 2012-02-29
PL2275086T3 (pl) 2012-09-28
US20110060279A1 (en) 2011-03-10
EP2453907A2 (en) 2012-05-23
RS52367B (sr) 2012-12-31
US7855176B1 (en) 2010-12-21

Similar Documents

Publication Publication Date Title
DK2275086T3 (da) Reduceret volumenformulering af glatirameracetat og fremgangsmåder til administration heraf
DK2254590T3 (da) Fremgangsmåder og præparater til oral administration af insulin
DK2493474T3 (da) Fremgangsmåder og sammensætninger til vedvarende afgivelse af lægemidler
DK2531181T3 (da) Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf
DK2493531T4 (da) Lægemiddelfremføringsindretninger og fremgangsmåde til samling
DK2558133T3 (da) Coatinger til fremstillingen og anvendelse af polyhydroxyalkanoat-lægemiddelindretninger
DK3045043T3 (da) Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
DK2273975T3 (da) Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
SG10201912687WA (en) Stable Pharmaceutical Composition And Methods Of Using Same
DK2419670T3 (da) Leveringsmetode og sammensætninger
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK2714135T3 (da) Medikamentadministrationsanordning og fremgangsmåde til styring af anordningen
DK3321355T3 (da) Fremgangsmåder og sammensætninger til klinisk afledning af en allogen celle og terapeutiske anvendelser
DK3011975T3 (da) Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf
DK2432456T3 (da) Faste farmaceutiske sammensætninger og fremgangsmåder til fremstilling deraf
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
DK3199533T3 (da) Pyrazolforbindelse og farmaceutisk anvendelse deraf
DK2525789T3 (da) Farmaceutiske formuleringer af naproxen til softgel-indkapsling og kombinationer deraf
DK2525782T3 (da) Formuleringer af nanobærere og fremgangsmåder til fremstilling deraf
DK2525827T3 (da) Farmaceutiske formuleringer af loratadin til indkapsling og kombinationer deraf
DK2403354T3 (da) Formulering af astaxanthin-derivater og anvendelse heraf
DK2588097T3 (da) Farmaceutiske sammensætninger omfattende paracetamol og fremgangsmåde til fremstilling af samme
DK2482799T3 (da) Farmaceutiske aerosolformuleringer af formoterol og beclometasondipropionat